FDA will not fire staff pending Congress' move
This article was originally published in Clinica
Executive Summary
As the US Congress left last week for its month-long recess without passing a major Food and Drug Administration reform bill, FDA Commissioner Andrew von Eschenbach vowed that the FDA would use reserve funds rather than layoff employees. House and Senate leaders could not agree on a reform bill, which contains numerous post-market safety changes as well as reauthorisation for medical device and drug user fee programmes, and so the law requires the agency FDA to begin sending "reduction in force" notices to employees paid by those programmes.
You may also be interested in...
Probiotics And Cold Remedies Boost Recordati In 2023
Italy's Recordati saw its OTC sales grow by 10% in 2023 driven by the recovery of the cough & cold market and a growing demand for probiotics.
Falling Sales Force New Priorities At Roche
The Swiss major brings a new ruthlessness to the compounds in its pipeline: if they’re not first or best, they’re out.
Human Cell-Secreted Proteins Offer A Wellspring Of Potential Therapeutics
CEO Hanadie Yousef leads Juvena Therapeutics in utilizing an AI-based platform that analyzes cell-secreted proteins to identify potential therapeutics. One of their first near-clinical assets could complement GLP-1s.